Mayne Pharma Group (AU:MYX) has released an update.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Mayne Pharma Group has announced a significant change in the securities interest of its director, Shawn Patrick O’Brien. As of December 2, 2024, O’Brien acquired an additional 301,455 Performance Rights and 35,170 RSU Performance Rights, increasing his direct holdings. This change reflects O’Brien’s growing stake in the company, potentially signaling confidence in Mayne Pharma’s future performance.
For further insights into AU:MYX stock, check out TipRanks’ Stock Analysis page.